modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models....
pharmacy specializing in personalized medication services, announced a strategic New Year's expansion of its compounded GLP-1 weight management program. The expansion provides increased access to compounded tirzepatide and semaglutide, perfectly...
OCuSOFT Inc. a privately-held eye care pharma company recognized as developing the first eyelid hygiene cleansing agent, proudly announces the launch of Retaine® Omega Forté™, a highly purified omega-3 nutritional supplement formulated to provide...
BIOCORNEUM®, the leading brand in professional scar and skin recovery, announced the immediate availability of its new Bruise Care System. The innovative dual-approach regimen is designed to help patients prepare for and recover more quickly from...
MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of orthobiologic solutions, announced the launch of...
For more than forty years, Trauma Intervention Programs (TIP) has stood beside individuals and families during their most devastating moments, providing immediate, on-scene emotional first aid in the aftermath of tragedy. TIP recently announced...
with user-centric design to maximize output and comfort: Hospital-Strength Power: Provides hospital-grade suction with 12 adjustable strength levels and 2-phase technology. Baby-Inspired Pumping Styles: Features three distinct pumping styles and a...
treatment for 30 eligible patients through CFAO’s Smiles4Canada program, a public health goodwill program founded in 2016 to put a smile, both figuratively and literally, on a young person with significant orthodontic needs, whose family does not...
blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4...
from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction. (GEJ) adenocarcinoma in ESMO Open, characterizing the management of...
waste management. Millions of Americans rely on self-administered injectable medications every day, including insulin, GLP-1 therapies, migraine biologics, and autoimmune biologics. The resulting waste (billions of discarded needles and syringes)...
that enrollment of the first participants has been completed in a Phase 2 clinical trial in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer...
for Reconstitution, for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD). This new kit includes 100 mL of Water for Infusion (WFI) and continues to feature the nextaro® reconstitution device, offering enhanced...
tract, supporting sustained therapeutic exposure throughout the day. Aizhida was approved by the U.S. FDA in March 2021 as a once-daily treatment option for patients with ADHD 6 years of age and older. ADHD is a common, chronic neurodevelopmental...
brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will...
Measures MOCA (Montreal Cognitive Assessment) scores remained unchanged at week 22, compared to baseline (Baseline, 13.5 and week 22, 14) suggesting no decline in cognitive function over the 22-week period. CDR-FTLD scores did not significantly...
diseases, announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service...
the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's...
Bioepis Co., Ltd. announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to...
neuromodulation. Systematic variation of stimulation parameters produced dose-dependent changes in alpha-band (8–12 Hz) and gamma-band (78–82 Hz) neural activity, confirming that stimulation reliably modulates physiological signals....
